Schizophrenia Market Size in the 7MM was ~USD 7,972.0 million in 2022, estimated DelveInsight

DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, as well as the Schizophrenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Schizophrenia Market is an evolving segment of the global healthcare landscape, driven by the increasing prevalence of the disorder and the continuous development of innovative treatment options. The market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Schizophrenia Market with DelveInsight's In-Depth Report @ Schizophrenia Market Size [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Schizophrenia Market Report

* In November 2024:- Boehringer Ingelheim- This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia.
* In November 2024:- Karuna Therapeutics- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease. The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
* As per DelveInsight analysis, in 2023 the total diagnosed prevalent cases of schizophrenia in the 7MM were found to be approximately 3.8 million cases out of which the US accounted for nearly 1.4 million cases. It is anticipated that these numbers will rise by 2034 owning to advancements in psychiatric research and diagnostic criteria, potentially resulting in a more precise identification and diagnosis of schizophrenia on a global scale.
* DelveInsight's analysis suggests that males have a higher susceptibility to schizophrenia, influenced by genetic, hormonal, and neurodevelopmental factors. In 2023, the diagnosed prevalence of schizophrenia in the US was approximately 767 thousand for males and 664 thousand for females. Projections indicate that these figures may vary over the forecast period (2024-2034).
* According to the epidemiological model, the prevalence of diagnosed cases of schizophrenia differs based on severity levels across the 7MM. In 2023, Japan recorded approximately 450 thousand diagnosed cases of mild schizophrenia, followed by roughly 173 thousand cases of moderate severity and 171 thousand cases of severe severity. These figures are projected to change in the forecast period from 2024 to 2034.
* The leading Schizophrenia Companies such as Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics , and others.
* Promising Schizophrenia Therapies such as Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231) , and others.

Stay ahead in the Schizophrenia Therapeutics Market with DelveInsight's Strategic Report @ Schizophrenia Market Outlook [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Schizophrenia Epidemiology Segmentation in the 7MM

* Total Schizophrenia Prevalent Cases
* Total Schizophrenia Diagnosed Cases
* Schizophrenia Gender-specific Cases
* Schizophrenia Severity-specific Cases
* Schizophrenia Age-specific Treated Cases
* Schizophrenia Treated Cases

Download the report to understand which factors are driving schizophrenia epidemiology trends @ Schizophrenia Prevalence [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Schizophrenia Treatment Market

The mainstay of treatment includes medication and psychosocial therapy that can help manage the condition. Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics, recommended as first-line treatment for schizophrenia, divided into first-generation (FGAs) and second-generation (SGAs) categories, are the primary pharmacological interventions. For some patient groups, treatment strategies include a combination of neuroleptics and antiepileptic. Both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are available for each generation. In practice, both FGA and SGA are used to manage schizophrenia.

Schizophrenia Marketed Drugs

* ABILIFY MAINTENA (aripiprazole): Otsuka Pharmaceutical/Lundbeck
* UZEDY (risperidone): Teva Pharmaceuticals/MedinCell

Schizophrenia Emerging Drugs

* Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
* Brilaroxazine (RP-5063): Reviva Pharmaceuticals

Get In-Depth Knowledge on Schizophrenia Market Trends and Forecasts with DelveInsight @ Schizophrenia Treatment Market [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Schizophrenia Drugs Market Insights

Schizophrenia treatment typically involves a combination of medication and psychosocial interventions aimed at managing the condition effectively. Pharmacotherapy plays a pivotal role in addressing schizophrenia symptoms, with a wide array of mono and combination pharmacological options available. Antipsychotic medications, categorized into first-generation (FGAs) and second-generation (SGAs), are commonly prescribed as first-line treatments. Some treatment approaches may involve a combination of antipsychotics and antiepileptic medications, tailored to specific patient groups. Both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are accessible options within each generation of antipsychotics. In clinical practice, a blend of both FGAs and SGAs is often utilized to effectively manage schizophrenia symptoms.

Schizophrenia Market Outlook

The SchizophreniaMarket is replete with antipsychotic drugs utilizing diverse routes of administration (ROA), with a primary focus on dopamine modulation, establishing them as the conventional approach to treating schizophrenia. FDA-approved oral antipsychotics include CAPLYTA (lumateperone), VRAYLAR (cariprazine), LYBALVI (olanzapine and samidorphan), REXULTI (brexpiprazole), LATUDA (lurasidone hydrochloride), along with other oral therapies such as FANAPT and ABILIFY MYCITE.

Schizophrenia is a severe and chronic mental disorder characterized by distorted thinking, perception, emotions, language, sense of self, and behavior. Its impact extends beyond patients to family members, caregivers, and society due to its lifelong nature and the likelihood of relapses. The disorder progresses through stages, including prodromal, active, and residual, each marked by specific symptoms such as hallucinations, suspiciousness, delusions, depression, withdrawal, anxiety, and difficulty concentrating. The treatment options for schizophrenia include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT).

Unlock Strategic Insights with DelveInsight's Comprehensive Schizophrenia Market Report @ Schizophrenia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Schizophrenia Market Report

* Coverage- 7MM
* Schizophrenia Companies- Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
* Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
* Schizophrenia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Schizophrenia Unmet Needs, KOL's views, Analyst's views, Schizophrenia Market Access and Reimbursement

Table of Content

1. Key Insights

2. Report Introduction

3. Schizophrenia Market Overview at a Glance

4. Methodology of Schizophrenia Epidemiology and Market

5. Executive Summary of Schizophrenia

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Schizophrenia: Market Analysis

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-market-size-in-the-7mm-was-usd-79720-million-in-2022-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.